(Q39983645)

English

Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

0 references

author name string

Teemu T Tolonen

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Teuvo L J Tammela

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Paula M Kujala

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Vilppu J Tuominen

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Jorma J Isola

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Tapio Visakorpi

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

18 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

108

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1430-1438

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Survival following primary androgen deprivation therapy among men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

PSA decline is an independent prognostic marker in hormonally treated prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Roles of the EZH2 histone methyltransferase in cancer epigenetics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

The polycomb group protein EZH2 is involved in progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

MCM7 interacts with androgen receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

MCM7 amplification and overexpression are associated with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

The application of JPEG2000 in virtual microscopy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

ImageJ for microscopy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Clinical implications of changing definitions within the Gleason grading system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10253.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2011.10253.X

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39983645&oldid=1881714700"